2026/04/15 by Inmaculada Rodriguez-Martin, Martin Kerick, Carlos Rangel-Peláez +97 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Connective Tissue Growth Factor Research #Inflammatory Myopathies and Dermatomyositis #Systemic Sclerosis and Related Diseases
paper · doi:10.1016/s2665-9913(25)00376-5
openalex publication_date 2026/04/15 · openalex created_date 2026/04/16 · openalex updated_date 2026/08/01
BACKGROUND: Systemic sclerosis is an immune-mediated inflammatory disease with marked sex differences in prevalence and severity. Although genome-wide association studies (GWAS) have advanced the understanding of systemic sclerosis genetics, sex-aware approaches remain scarce. We aimed to address this gap by examining autosomal sex-specific genetic factors in systemic sclerosis. METHODS: Based on a chromosomal definition of sex, we conducted a sex-stratified autosomal meta-analysis of GWAS in systemic sclerosis. We retrieved patient-level and control data from a previous GWAS for systemic sclerosis and newly recruited participants from an international multicentre collaboration (data cutoff June 1, 2024). Adult patients (aged ≥18 years) were required to meet the 2013 American College of Rheumatology-European League Against Rheumatism classification criteria or the criteria for early systemic sclerosis proposed by LeRoy and Medsger, 2001. Patients with systemic sclerosis were compared with healthy controls through sex-stratified analyses. Sex-specific loci were functionally annotated and a sex-differential expression analysis was performed to validate the findings. Additionally, we performed a drug repurposing analysis to explore the clinical implications of our findings. People with lived experience of systemic sclerosis were not involved in the study design or conduct. FINDINGS: ), and five previously known loci now characterised as female-specific. Functional analyses implicated 39 candidate genes, of which five (IL12RB2, ARHGAP31, UBL7, CSK, and MPI) showed sex-differential expression in patients with systemic sclerosis. Two approved drugs, fostamatinib and dasatinib, were identified as potential repurposing candidates for systemic sclerosis sex-aware treatment. INTERPRETATION: We report the first evidence of sex-specific genetic architecture in systemic sclerosis. These findings offer insight into the molecular basis of sex differences in the disease, highlighting both IL12RB2 gene and interferon signalling. These results also support the development of sex-aware precision medicine approaches. FUNDING: Instituto de Salud Carlos III, EU's Seventh Framework Program, and European Federation of Pharmaceutical Industries and Associations companies.